Okyo Pharma executives buy shares on Nasdaq over two days in July 2026

OKYO Pharma Limited disclosed two share purchases by senior executives in Form 6-K filings dated July 22 and July 23, 2026.

On July 22, 2026, the company said its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 of the company's ordinary shares on NASDAQ at $1.40 per share.¹

A day later, on July 23, 2026, OKYO Pharma reported a separate transaction by its top executive: Chief Executive Officer Robert J. Dempsey purchased 15,000 of the company's ordinary shares on NASDAQ at $1.54 per share.²

Both filings describe OKYO Pharma as a company focused on developing therapies for neuropathic corneal pain and anterior segment eye diseases, with shares trading on Nasdaq under the ticker OKYO. The filings also note the company's plans for late-stage testing of its lead candidate: OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of the year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.²

Each announcement was furnished as Exhibit 99.1 and signed by Chief Financial Officer Keeren Shah, with the July 22 filing signed by Keeren Shah as Chief Financial Officer on July 22, 2026¹ and the July 23 filing signed by Keeren Shah as Chief Financial Officer on July 23, 2026.² Both reports state they are incorporated by reference into the company's Form F-3 registration statement, filed under Registration No. 333-293145.